MedTrace Logo

QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension

NCT06716970 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 810

Last updated 2024-12-06

No results posted yet for this study

Summary

The purpose of the study is to evaluate the efficacy and safety of QR12000 75mg, QR12000 150mg and Sacubitril/valsartan 200mg in patients with moderate to severe essential hypertension.

Conditions

  • Essential Hypertension

Interventions

DRUG

QR12000 75mg

QR12000 75mg QD

DRUG

QR12000 75mg placebo

Matching placebo of QR12000 75mg QD

DRUG

QR12000 150mg

QR12000 150mg QD

DRUG

QR12000 150mg placebo

Matching placebo of QR12000 150mg QD

DRUG

Sacubitril/valsartan 200mg

Sacubitril/valsartan 200mg QD

DRUG

Sacubitril/valsartan 200mg placebo

Matching placebo of Sacubitril/valsartan 200mg QD

Sponsors & Collaborators

  • Wuhan Createrna Science and Technology Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-30
Primary Completion
2026-04-30
Completion
2027-02-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06716970 on ClinicalTrials.gov